5AYS image
Deposition Date 2015-09-02
Release Date 2016-06-08
Last Version Date 2023-11-08
Entry Detail
PDB ID:
5AYS
Title:
Crystal structure of SAUGI/HSV UDG complex
Biological Source:
Source Organism:
Host Organism:
Method Details:
Experimental Method:
Resolution:
2.09 Å
R-Value Free:
0.22
R-Value Work:
0.19
R-Value Observed:
0.19
Space Group:
P 1
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:Uracil-DNA glycosylase
Gene (Uniprot):UL2
Chain IDs:A, C (auth: B)
Chain Length:256
Number of Molecules:2
Biological Source:Human herpesvirus 1 (strain 17)
Polymer Type:polypeptide(L)
Molecule:Uncharacterized protein
Chain IDs:B (auth: C), D
Chain Length:112
Number of Molecules:2
Biological Source:Staphylococcus aureus
Primary Citation
Using structural-based protein engineering to modulate the differential inhibition effects of SAUGI on human and HSV uracil DNA glycosylase.
Nucleic Acids Res. 44 4440 4449 (2016)
PMID: 26980279 DOI: 10.1093/nar/gkw185

Abstact

Uracil-DNA glycosylases (UDGs) are highly conserved proteins that can be found in a wide range of organisms, and are involved in the DNA repair and host defense systems. UDG activity is controlled by various cellular factors, including the uracil-DNA glycosylase inhibitors, which are DNA mimic proteins that prevent the DNA binding sites of UDGs from interacting with their DNA substrate. To date, only three uracil-DNA glycosylase inhibitors, phage UGI, p56, and Staphylococcus aureus SAUGI, have been determined. We show here that SAUGI has differential inhibitory effects on UDGs from human, bacteria, Herpes simplex virus (HSV; human herpesvirus 1) and Epstein-Barr virus (EBV; human herpesvirus 4). Newly determined crystal structures of SAUGI/human UDG and a SAUGI/HSVUDG complex were used to explain the differential binding activities of SAUGI on these two UDGs. Structural-based protein engineering was further used to modulate the inhibitory ability of SAUGI on human UDG and HSVUDG. The results of this work extend our understanding of DNA mimics as well as potentially opening the way for novel therapeutic applications for this kind of protein.

Legend

Protein

Chemical

Disease

Primary Citation of related structures